Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer

ABSTRACT: Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer

PROVIDER: PRJEB29155 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2838520.fastq.gz	Fastqsanger.gz
	ERR2838530.fastq.gz	Fastqsanger.gz
	ERR2838540.fastq.gz	Fastqsanger.gz
	ERR2838521.fastq.gz	Fastqsanger.gz
	ERR2838531.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Inverse Agonists of the Androgen Receptor

Project description:Inverse Agonists of the Androgen Receptor

| PRJNA848752 | ENA

Inverse Agonists of the Androgen Receptor

Project description:We report the efficacy of androgen receptor inverse agonists (ARIAs) in altering androgen receptor (AR) transcriptional activity. Through RNA-sequencing studies in a panel of prostate cancer cell lines and patient derived xenograft models, we demonstrate ARIAs succcessfully inhibit androgen response gene sets. ChIP-seq and CUT&RUN studies demonstrate H3K27ac decreases at AR-target genes in response to treatment. AR and NCOR1/2 localizes at these regions of acetylation loss. HiChIP further revealed loss of 3D connectivity in reponse to ARIA treatment,

2023-06-25 | GSE205980 | GEO

Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer

Project description:Work published by Wang et al. described pharmacological inhibition of RORg with an inverse agonist (SR2211) which led to a decrease in AR gene expression and a reduction in AR protein, which led to the loss of an AR gene expression signature. We have developed a novel, specific, RORg inverse agonist (AZ RORgi) and have studied its effects on the transcriptome of LNCAP cell lines following 24 & 48 hours of treatment. We compare this to SR2211 as well as Enzalutamide, an AR antagonist. We show that Enzalutamide and SR2211 primarily act via the androgen receptor, whereas AZ RORgi does not modulate gene expression in these cell lines.

2019-12-31 | E-MTAB-7294 | biostudies-arrayexpress

The effects of enzalutamide on androgen-dependent and androgen-independent prostate cancer cells.

Project description:To investigate the mechanisms of drug resistance and castration resistance in prostate cancer, we performed proteomic sequencing on androgen-dependent prostate cancer cells (LNCaP) and androgen-independent cells (AI) treated with enzalutamide.

2024-11-26 | PXD058261 |

E-MTAB-7294

Project description:Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer

2025-01-23 | E-MTAB-7294 | ExpressionAtlas

Androgen-sensitive glycomembrane protein expression in LNCaP prostate tumor cells

Project description:Aberrant androgen receptor (AR)-mediated transcription is a critical driver in progression of human prostate cancer. It's known that different doses of androgens can elicit differential transcriptional and proliferative responses in prostate-tumor cells. Here, we set out to examine the androgenic regulation of glycoprotein expression in the membrane fraction of prostate-tumor cells that could serve as mediators or markers of androgen-induced proliferative responses observed in prostate-tumor cells. A bioanalytical workflow involving lectin-affinity chromatography and label-free quantitative mass spectrometry was used to identify androgen-sensitive glycomembrane protein expression associated with androgen-mediated proliferation. This study would facilitate the identification of surface membrane proteins involved in androgen-mediated proliferation and provide potential therapeutic targets in the detection treatment of proliferation prostate-tumors.

2022-03-01 | PXD002913 | Pride

Structure–Function Relationships and Therapeutic Potential of Non-Covalent PPARγ Inverse Agonists

Project description:Peroxisome proliferator-activated receptor gamma (PPARγ) is a validated therapeutic target for type 2 diabetes (T2D), but current FDA-approved agonists such as the glitazones are limited by adverse effects. SR10171, a non-covalent partial inverse agonist with modest binding potency, improves insulin sensitivity in mice without bone loss or marrow adiposity. Here, we characterize a series of SR10171 analogs to define structure-function relationships using biochemical assays, hydrogen-deuterium exchange (HDX), and computational modeling. Analogs featuring flipped indole scaffolds with alkyl substitutions exhibited 10-100-fold enhanced binding to PPARγ while retaining inverse agonist activity. HDX and molecular dynamic simulations revealed that ligand-induced dynamics within ligand-binding pocket and AF2 domain correlate with enhanced receptor binding. Lead analogs restored receptor activity in loss-of-function PPAR variants and improved insulin sensitivity in adipocytes from a diabetic patient. These findings provide mechanistic insights into non-covalent PPARγ modulation establishing a framework for developing safer, next-generation insulin sensitizers for metabolic disease therapy.

2025-11-15 | PXD066095 | Pride

gene differentially expressed in androgen independent prostate cancer

Project description:Progression to androgen independent is the main cause of death in prostate cancer, and the mechanism is still unclear. By reviewing the expression profiles of 26 prostate cancer samples in a holistic view, we found a group of genes differentially expressed in androgen independent compared with androgen dependent groups (p value< 0.01, t test). Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5 (TXNDC5), tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), ribosomal protein S19 (RPS19) and Janus kinase 2 (JAK2) up-regulated in androgen independent prostate cancer, which could play important roles in the transition from androgen dependent to androgen independent and could be biomarkers of prognosis. The main aim was comparing the androgen dependent and androgen independent prostate cancer to identify differentially expressed genes. In addition, we added several normal prostate tissue sample for comparisons. Totally 29 experiments were performed without replicates. 3 for normal prostate tissue, 8 for androgen independent cancer and 18 for androgen dependent prostate cancer. In all experiments, the reference samples are common reference, a pool with unrelated fetal tissues.

2007-09-09 | E-GEOD-5803 | biostudies-arrayexpress

Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy

Project description:Radiotherapy (RT) with or without androgen deprivation therapy (ADT) is standard salvage therapy for men with local or biochemical recurrence of prostate cancer after prostatectomy, but there is an unmet need for biomarkers to identify potential non-responders. We hypothesized that androgen receptor splice variants (ARVs) are detectable in primary prostate cancer and may modulate response to salvage RT+ADT. We identified a retrospective cohort of prostate cancer patients treated with prostatectomy followed by salvage RT + ADT, and we performed targeted RNA-seq of archival formalin-fixed paraffin-embedded prostatectomy samples to comprehensively characterize the landscape of ARVs.

2026-01-07 | GSE268636 | GEO

Androgen regulated gene expression in human prostate

Project description:Androgens are a prequisite for the development of human prostate and prostate cancer. Androgen action is mediated via androgen receptor. Androgen ablation therapy is used for the treatment of metastasized prostate cancer. The aim of the study was to identify genes differentially expressed in benign human prostate, prostate cancer and in prostate tissue three days after castration. These genes are potential diagnostic and therapeutic targets for prostate cancer and benign prostatic hyperplasia. We used microarrays to examine the gene expression profiles in benign prostate adjacent to prostate cancer and prostate cancer in radical prostatectomy specimens and in prostate tissue samples taken 3 days after surgical castration performed for treatment of prostate cancer.

2012-06-20 | GSE32982 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data